ArticleESMO open2026
Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Trop-2-directed antibody-drug conjugate sacituzumab govitecan (SG) has shown significant benefit in metastatic triple-negative breast cancer (mTNBC) in clinical trials. However, evidence about its effectiveness and safety in real-world heterogeneous patient populations is limited. This multicenter study, including the largest European and second-largest worldwide real-world cohort of SG-treated patients with mTNBC, offers valuable insights for its use in routine clinical practice. MATERIALS AND
methodsThis analysis included 256 women with mTNBC treated with SG across 17 Italian oncology centers, consisting of 217 retrospectively identified patients and 39 prospectively enrolled patients. Treatment activity and safety were assessed according to RECIST v1.1 and Common Terminology Criteria for Adverse Events del National Cancer Institute (NCI-CTCAE) v5.0 criteria.
resultsMedian patient age was 54 years (range 26-80), and 70.7% had TNBC at initial diagnosis. The median interval from metastatic diagnosis to SG initiation was 16 months (range 0-115), with a median of two prior treatment lines (range 0-7). Frequent metastatic sites were lymph nodes (60.9%), bone (43.0%), lung (42.6%), liver (33.2%), and brain (26.2%). Overall, 37.5% achieved complete or partial response, 27.7% had stable disease, and 31.2% experienced progression. At a median follow-up of 17.4 months, 202 patients had progressed, and 139 had died. Median real-world progression-free survival was 6.4 months [95% confidence interval (CI) 5.3-7.3] and median real-world overall survival was 13.6 months (95% CI 11.5-15.5). The most common treatment-related adverse events were alopecia (69.1%), neutropenia (57.0%), nausea (49.6%), anemia (46.9%), and diarrhea (36.7%). Grade 3-4 neutropenia occurred in 18.0% and 5.9%, respectively. Dose reductions were required in 36.5%, and 2.7% discontinued treatment.
conclusionsSG demonstrated durable clinical benefit and manageable toxicity in patients with mTNBC, highlighting the importance of optimized adverse-event management. The size and heterogeneity of the study population, including the largest reported cohort of patients with central nervous system metastases, support the robustness of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.